Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04103476 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Advancing Postmenopausal Preventive Therapy

Study acronym: APPT
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 400 to confirmed 385
    • Site details revised
    v4
  2. Re-verified, no change to tracked fieldsv3
  3. Primary completion date: Jun 30, 2024 to Oct 31, 2026
    • Start date changed from estimate of Oct 1, 2019 to Apr 13, 2021
    • Study completion date: Dec 31, 2024 to Dec 31, 2026
    • Site contact updated
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Advancing Postmenopausal Preventive Therapy (APPT) is a randomized, double-blinded, placebo-controlled trial designed to determine the effects of tissue selective estrogen complex (TSEC) therapy on the progression of subclinical atherosclerosis and cognitive decline in 360 healthy postmenopausal women.
Trial Details
NCT Number NCT04103476
Lead Sponsor University of Southern California
Collaborators: National Institute on Aging (NIA)
Conditions
(from sponsor)		 Atherosclerosis, Cognitive Decline
Related terms Atherosclerosis, Cognitive Dysfunction
Enrollment 385 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov